GSK’s 3 billion pounds sterling peak sales goal for its multiple myeloma drug Blenrep appears increasingly attainable thanks ...

GSK is carving out a niche for Blenrep in the second-line multiple myeloma setting, for which it projects a multi-blockbuster ...

Johnson & Johnson (JNJ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

GSK's drive to resurrect its multiple myeloma therapy Blenrep has continued with new data from the DREAMM-7 trial showing an ...

Assetmark Inc. boosted its stake in shares of Genmab A/S (NASDAQ:GMAB – Free Report) by 16.2% during the 3rd quarter, Holdings Channel.com reports. The institutional investor owned 82,629 shares of ...

Deutsche Bank lowered the firm’s price target on Genmab (GMAB) to DKK 2,250 from DKK 2,500 and keeps a Buy rating on the shares.

At Mar-a-Lago, ‘Uncle’ Elon Musk Puts His Imprint on the Trump Transition He’s on the patio. He’s on the golf course. Everywhere President-elect Trump looks, there is the world’s richest ...

GSK reported positive survival data for Blenrep combined with bortezomib and dexamethasone in multiple myeloma DREAMM-7 trial, outperforming daratumumab combination therapy. GSK plans US relaunch in ...